Q2 FY2026 EarningsQ2 FY2026 results missed consensus estimates on the bottom line, with a GAAP net loss of $34.5M vs. the $31.9M expected. GAAP EPS of -$1.55 missed the mean estimate of -$1.42, driven by higher-than-expected R&D and G&A expenses due to NGN-401 clinical activities and stock-based compensation. However, the company significantly strengthened its balance sheet via a $144M offering, extending its cash runway into Q1 2029, while reporting positive Phase 1/2 clinical data for Rett syndrome.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Neurogene(NGNE) the EBIT is -36.67 M (-40.6%), Miss estimate;the EPS is -1.53 (-45.71%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
TBA--
0.00B--
----
EBITMiss expectations
-0.04B40.60%
-0.03B24.18%
-0.00B16.42%
EPSMiss expectations
-1.5345.71%
-1.3932.38%
-0.140013.33%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf